Technical aspects of minimal residual disease detection in carcinoma patients

Seminars in Surgical Oncology

Volumn 20, Issue 4, 2001, Pages 252-264

  Lacroix, Jeannine ^a   Von Knebel Doeberitz, Magnus ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Disseminated cancer cells; DNA alterations; Immunocytochemistry; Immunomagnetic enrichment techniques; Micrometastasis; Minimal residual disease; RT PCR

Indexed keywords

CANCER RECURRENCE; CARCINOMA; CELL SEPARATION; CELL STRUCTURE; DIAGNOSTIC PROCEDURE; DISSEMINATED CANCER; GENE MUTATION; HUMAN; IMMUNOCYTOCHEMISTRY; METASTASIS; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TREATMENT INDICATION;

CARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM, RESIDUAL; NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0034768115     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/ssu.1042     Document Type: Review

References (92)

1. Global cancer statistics
2. Cancer undefeated
3. Imaging liver metastases: Current limitations and future prospects
4. Early detection of lung cancer: Clinical perspectives of recent advances in biology and radiology
5. Nucleic acid based techniques for the detection of rare cancer cells in clinical samples
6. Detection and clinical importance of micrometastatic disease
7. Disseminated tumor cells: Diagnosis, prognostic relevance, and phenotyping
8. Disseminated tumor cells versus micrometastasis: Definitions and problems
9. Transrectal ultrasound-guided biopsy causes hematogenous dissemination of prostate cells as determined by RT-PCR
10. Detection and clearance of prostate cells subsequent to ultrasound-guided needle biopsy as determined by multiplex nested reverse transcription polymerase chain reaction assay
11. Detection of hematogenic tumor cell dissemination in patients undergoing resection of liver metastases of colorectal cancer
12. Comparative analysis of tumor cell dissemination in mesenteric, central, and peripheral venous blood in patients with colorectal cancer
13. Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients
14. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer
15. Preservation of RNA for functional genomic studies: A multidisciplinary tumor bank protocol
16. Safe separation of sputum cells from mucoid glycoprotein
17. Sensitive detection of rare cancer cells in sputum and peripheral blood samples of patients with lung cancer by PreproGRP-specific RT-PCR
18. Immunomagnetic separation for enrichment and sensitive detection of disseminated tumour cells in patients with head and neck SCC
19. Immunomagnetic cell enrichment detects more disseminated cancer cells than immunocytochemistry in vitro
20. Immunomagnetic enrichment of disseminated epithelial tumor cells from peripheral blood by MACS
21. Rapid enrichment and detection of melanoma cells from peripheral blood mononuclear cells by a new assay combining immunomagnetic cell sorting and immunocytochemical staining
22. Analysis of surgical margins with the molecular marker EIF4E: A prognostic factor in patients with head and neck cancer
23. Mapping of resection margins of oral cancer for p53 overexpression and chromosome instability to detect residual (pre)malignant cells
24. Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status
25. Prognostic significance of micrometastatic bone marrow involvement
26. Molecular detection and characteriation of circulating tumour cells and micrometastases in solid tumours
27. Detection and clinical relevance of micrometastatic cancer cells
28. Detection and relevance of immunohistochemically identifiable tumor cells in lymph nodes
29. Comparative genomic hybridization: Uses and limitations
30. Fluorescence in situ hybridization: Uses and limitations
31. Incidence and functional consequences of HMLH1 promoter hypermethylation in colorectal carcinoma
32. Aging, methylation and cancer
33. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
34. Utilization of K-ras mutations identified in stool DNA for the early detection of colorectal cancer
35. Restriction digest PCR (RD-PCR) for the analysis of gene mutations. Application to ki-ras
36. Detection of K-ras mutation in colonic effluent samples from patients without evidence of colorectal carcinoma
37. Frequent detection of ras and p53 mutations in brush cytology samples from lung cancer patients by a restriction fragment length polymorphism-based "enriched PCR" technique
38. K-ras mutations in stools and tissue samples from patients with malignant and nonmalignant pancreatic diseases
39. Significance of K-ras mutation and CEA level in pancreatic juice in the diagnosis of pancreatic cancer
40. Molecular stool screening for colorectal cancer. Using DNA markers may be beneficial, but large scale evaluation is needed
41. K-ras mutation in sputum of patients with or without lung cancer
42. Early detection of pancreatic cancer in patients with chronic pancreatitis: Diagnostic utility of a K-ras point mutation in the pancreatic juice
43. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer
44. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes
45. Use of reverse transcriptase polymerase chain reaction for diagnosis and staging of alveolar rhabdomyosarcoma, ewing sarcoma family of tumors, and desmoplastic small round cell tumor
46. Ectopic (illegitimate) transcription: New possibilities for the analysis and diagnosis of human genetic disease
47. Specificity of reverse transcriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro
48. Detection of micrometastasis through tissue-specific gene expression: Its promise and problems
49. High-sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood
50. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction
51. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay
52. Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: Correlation with pathological stage
53. Cytokeratins in the histological diagnosis of malignant tumors
54. Detection of disseminated colorectal cancer cells in lymph nodes, blood and bone marrow
55. Impact of cytokeratin-20 and carcinoembryonic antigen mRNA detection by RT-PCR in regional lymph nodes of patients with colorectal cancer
56. Detection of hematogenous micrometastasis in patients with transitional cell carcinoma
57. Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes
58. CK20 gene expression: Technical limits for the detection of circulating tumor cells
59. A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood
60. Lung cancer metastatic cells detected in blood by reverse transcriptase-polymerase chain reaction and dot-blot analysis
61. Detection of occult micrometastases in non-small cell lung carcinoma by reverse transcriptase-polymerase chain reaction
62. Detection of cytokeratin-19 transcripts by reverse transcriptase-polymerase chain reaction in lung cancer cell lines and blood of lung cancer patients
63. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients
64. Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow
65. Detection of occult tumor cells in peripheral blood from patients with small cell lung cancer by reverse transcriptase-polymerase chain reaction
66. Clinical trials of Herceptin (trastuzumab)
67. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients
68. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: Results of a 3-year median follow-up
69. Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status
70. Outcome of primary-breast-cancer patients with micrometastases: A long-term follow-up study
71. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer
72. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients
73. Cytokeratin-positive cells in bone marrow in comparison with other prognostic factors in colon carcinoma
74. Micrometastatic tumour cells in bone marrow of patients with gastric cancer: Methodological aspects of detection and prognostic significance
75. Individual development and UPA-receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer
76. Prognostic significance of bone marrow micrometastases in patients with gastric cancer
77. Disseminated epithelial tumor cells in bone marrow of patients with esophageal cancer: Detection and prognostic significance
78. Detection of occult bone marrow micrometastases in patients with operable lung carcinoma
79. Detection of disseminated lung cancer cells in lymph nodes: Impact on staging and prognosis
80. Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer
81. Immunocytochemical assessment of bone marrow aspirates for monitoring response to chemotherapy in small-cell lung cancer patients
82. A preliminary report on the usefulness of monoclonal antibodies to CA 15-3 and MCA in the detection of micrometastases in axillary lymph nodes draining primary breast carcinoma
83. Identification of occult micrometastases in pericolic lymph nodes of Duke's B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival
84. Benefits of D2 lymph node dissection for patients with gastric cancer and PN0 and PN1 lymph node metastases
85. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer
86. Relationship between early recurrence and micrometastases in the lymph nodes of patients with stage I non-small-cell lung cancer
87. Micrometastatic p53-positive cells in the lymph nodes of non-small-cell lung cancer: Prognostic significance
88. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases
89. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors
90. Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease
91. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival
92. Blood-based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: Long term follow-up confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) following radical prostatectomy